Traditional Chinese medicine composition for treating polycystic ovarian syndrome as well as preparation method and application thereof

By designing a composition composed of a variety of traditional Chinese medicines, the short effective period and ovarian hyperstimulation in the treatment of polycystic ovarian syndrome are solved, safe and reliable treatment effects are achieved, and the patients' ovulation disorders and ovarian polycystic ovulation in patients are improved. state.

CN118948966APending Publication Date: 2024-11-15NANJING UNIV OF TRADITIONAL CHINESE MEDICINE +1

Patent Information

Application Number
CN202411150805.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing technology has problems such as short effective period, ovarian hyperstimulation, low pregnancy rate and follicle flavinization in the treatment of polycystic ovary syndrome. In addition, the application of traditional Chinese medicine in this field has not yet been scientific and reasonable prescription combination, and lacks safety and reliability and no Treatment options for toxic side effects.

Method used

A kind of composition consists of Polygonatum, Scrophularia ginseng, Ophiopogon japonicus, Poria cocos, Atractylodes lancea, Magnolia officinalis, Fried Red Peony, Purple Salvia miltiorrhiza, Chicken Blood Vine, Fragrant Aconite, Purple Quartz, Soap Beans, Cinnamon Twig and Cinated Dragon Teeth The traditional Chinese medicine composition is extracted through water soaking and water addition in a multifunctional extraction tank, and is prepared into different dosage forms in combination with carriers. The principle of "monarch and ministers and assistants" is adopted to nourish yin and kidneys, eliminate phlegm and promote blood circulation, regulate menstruation and assist pregnancy.

Benefits of technology

This traditional Chinese medicine composition can effectively improve the symptoms of ovulation disorder, hyperandrogenemia, hyperinsulinemia and other symptoms in patients with polycystic ovarian syndrome, adjust the menstrual cycle, reduce androgen levels, improve the polycystic state of the ovarian under ultrasound, and clinical experiments It shows no toxic side effects and is safe and reliable to use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_5
    Figure SMS_5
  • Figure SMS_7
    Figure SMS_7
  • Figure SMS_9
    Figure SMS_9
Patent Text Reader

Abstract

The invention discloses a traditional Chinese medicine composition for treating polycystic ovarian syndrome and a preparation method thereof. The traditional Chinese medicine composition is prepared from 10-60 parts of rhizoma polygonati, 10-60 parts of radix scrophulariae, 10-60 parts of radix ophiopogonis, 10-60 parts of poria cocos, 10-60 parts of prepared rhizoma atractylodis, 6-36 parts of cortex magnoliae officinalis, 10-60 parts of fried radix paeoniae rubra, 10-60 parts of radix salviae miltiorrhizae, 15-90 parts of caulis spatholobi, 10-60 parts of prepared rhizoma cyperi, 10-60 parts of amethyst, 10-60 parts of spina gleditsiae, 10-60 parts of cassia twig and 20-120 parts of calcined dens draconis. The traditional Chinese medicine composition is obtained by screening through long-term clinical experience and clinical experiments, and experimental results show that the traditional Chinese medicine composition can obviously and continuously improve traditional Chinese medicine syndrome points of patients with polycystic ovarian syndromes, adjust the menstrual cycle and improve acne and hairy states of the patients; the traditional Chinese medicine composition can be used for treating the polycystic ovarian syndrome, reducing the androgen level, luteinizing hormone, the ratio of luteinizing hormone to follicle-stimulating hormone and the fasting insulin level of a patient and improving the ovarian polycystic state under ultrasound, has a good effect of treating the polycystic ovarian syndrome, and is free of toxic and side effects and safe and reliable in medication.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating polycystic ovary syndrome and a preparation method and application thereof. Background Art

[0002] Polycystic ovary syndrome (PCOS) is one of the most common reproductive and metabolic disorders in women and one of the main causes of infertility in women of childbearing age. The main features are ovulatory disorders, polycystic ovarian changes, and hyperandrogenemia (HA), often accompanied by reproductive dysfunction and abnormal glucose metabolism, and often occur in adolescence and childbearing age. The disease has the characteristics of polymorphism, and the main clinical manifestations are menstrual disorders, infertility, acne, hirsutism, obesity, and polycystic ovarian changes. The risk of long-term complications such as hypertension, type 2 diabetes, and endometrial hyperplasia or cancer is higher than that of normal women. The cause of this disease is unknown. The treatment principles of Western medicine are mainly to adjust the menstrual cycle, treat hyperandrogenemia and insulin resistance, and induce ovulation for those who want to have children. However, Western medicine treatment always faces problems such as short effective period, ovarian hyperstimulation, low pregnancy rate, and luteinization of follicles. Therefore, actively developing effective and safe therapeutic drugs has become one of the hot spots in the field of gynecological reproductive endocrinology.

[0003] PCOS patients often present with menstrual disorders or infertility, which is related to the imbalance of kidney yin and yang, and the disorder of qi and blood leading to phlegm and blood stasis. The main pathogenesis of PCOS is kidney yin deficiency and phlegm and blood stasis. Nourishing yin and tonifying the kidney, resolving phlegm and activating blood circulation are the fundamental methods of treatment. Kidney yin deficiency and insufficient Guishui cannot nourish sperm and eggs, and nourish the sea of ​​blood (endometrium), so the yin cannot grow to a certain weight, sperm and eggs are not mature, and pregnancy is difficult to form; long-term yin deficiency is bound to affect yang, and yang deficiency leads to phlegm and dampness accumulation, blocking Chongren and uterus, resulting in late menstruation or even cessation; phlegm and dampness accumulation and lipid membrane obstruction lead to obesity; phlegm turbidity blocks the uterine vessels, blood circulation is not smooth and blood stasis occurs, phlegm and blood stasis block each other, glue together to form symptoms, and capsule thickens, resulting in polycystic changes and enlargement of the ovaries. "Shenzhai Yishu" states: "If you want to nourish the kidney, you must first calm your heart. If your heart is calm, your kidney will naturally be strong." In treatment, the focus is on the interaction between the heart and the kidney. Only when the yin and yang of the heart and kidney interact can the yin and yang of the heart (brain)-kidney-uterus reproductive axis be promoted, thereby promoting the smooth transformation of the menstrual cycle. This prescription nourishes kidney yin and warms kidney yang, resolves phlegm and dampness, activates blood circulation, nourishes heart blood and calms the mind. The heart and kidney are integrated and coordinated (heart and kidney are treated together), protecting the yin and yang balance of the heart and kidney, and regulating the blood sea in the uterus to rise and fill as expected.

[0004] Traditional Chinese medicine has its unique advantages in the treatment of PCOS. Therefore, it is necessary to design and develop a Chinese medicine composition with reasonable composition, reliable efficacy and good safety for the treatment of PCOS based on the existing technology. Summary of the invention

[0005] Purpose of the invention: The purpose of the present invention is to solve the deficiencies of the prior art and provide a Chinese medicine compound composition with a scientific and reasonable ratio, good effects in treating ovulation disorders, hyperandrogenism, hyperinsulinemia, etc. in patients with polycystic ovary syndrome, and safe and reliable with low adverse reactions. Another purpose of the present invention is to provide a preparation method and application of the composition.

[0006] Technical solution: In order to achieve the above purpose, the technical solution adopted by the present invention is:

[0007] A Chinese medicine composition for treating polycystic ovary syndrome is prepared from the following raw materials in parts by weight:

[0008] 10-60 parts of polygonatum, 10-60 parts of figwort, 10-60 parts of ophiopogon, 10-60 parts of tuckahoe, 10-60 parts of

[0009] 10-60 parts of processed Atractylodes lancea, 6-36 parts of Magnolia officinalis, 10-60 parts of stir-fried Red Peony Root, 10-60 parts of Red Salvia miltiorrhiza

[0010] Millettia reticulata 15-90 parts, Cyperus rotundus 10-60 parts, Amethyst 10-60 parts, Gleditsia sinensis 10-60 parts

[0011] 10-60 parts of cinnamon twigs and 20-120 parts of calcined dragon teeth.

[0012] As a preferred embodiment, the above-mentioned Chinese medicine composition for treating polycystic ovary syndrome is made of the following raw materials in parts by weight:

[0013] 10-30 parts of Polygonatum sibiricum, 10-30 parts of Scrophularia ningpoensis, 10-30 parts of Ophiopogon japonicus, 10-30 parts of Poria cocos

[0014] 10-30 parts of processed Atractylodes lancea, 6-18 parts of Magnolia officinalis, 10-30 parts of stir-fried Red Peony Root, 10-30 parts of Red Salvia miltiorrhiza

[0015] Millettia reticulata 10-45 parts, Cyperus rotundus 10-30 parts, Amethyst 10-30 parts, Gleditsia sinensis 10-30 parts

[0016] 10-30 parts of cinnamon twigs and 20-60 parts of calcined dragon teeth.

[0017] As a more preferred embodiment, the above-mentioned Chinese medicine composition for treating polycystic ovary syndrome is made of the following raw materials in parts by weight:

[0018] 10 parts of polygonatum, 10 parts of figwort, 10 parts of ophiopogon, 10 parts of tuckahoe, 10 parts of

[0019] 10 parts of processed Atractylodes lancea, 6 parts of Magnolia officinalis, 10 parts of stir-fried Red Peony Root, 10 parts of Red Salvia miltiorrhiza

[0020] 15 parts of Millettia reticulata, 10 parts of processed Cyperus rotundus, 10 parts of Amethyst, 10 parts of Gleditsia sinensis, 10 parts of

[0021] 10 parts of cinnamon twigs and 20 parts of calcined dragon teeth.

[0022] The method for preparing the Chinese medicine composition for treating polycystic ovary syndrome of the present invention comprises the following steps:

[0023] Take processed polygonatum, figwort, ophiopogon, tuckahoe, processed atractylodes, magnolia bark, stir-fried red peony root, salvia miltiorrhiza, millettia reticulata, processed cyperus, purple quartz, sapodilla thorn, cassia twig, and calcined dragon tooth according to weight proportions, first soak them in water, then put them in a multifunctional extraction tank, add water to extract, combine the extracts, and concentrate; take the concentrate and a pharmaceutically acceptable carrier to prepare granules, powders, tablets, capsules, pills or mixtures.

[0024] As a preferred embodiment, the method for preparing the above-mentioned Chinese medicine composition for treating polycystic ovary syndrome comprises the following steps:

[0025] Take processed polygonatum, scrophularia, ophiopogon, tuckahoe, processed atractylodes, magnolia bark, stir-fried red peony root, salvia miltiorrhiza, millettia reticulata, processed cyperus, purple quartz, sapodilla thorn, cassia twig, and calcined dragon tooth by weight, first soak them in 6 to 15 times the amount of water, then extract them in a multifunctional extraction tank for 1 to 2 hours, then add 6 to 15 times the amount of water of the medicinal materials, extract for 1 to 2 hours, filter, combine the secondary extracts, and concentrate; take the concentrate and a pharmaceutically acceptable carrier to prepare granules, powders, tablets, capsules, pills or mixtures.

[0026] As a more preferred solution, the method for preparing the Chinese medicine composition for treating polycystic ovary syndrome of the present invention comprises the following steps:

[0027] First, take each medicinal material by weight, soak it in water for 1 to 2 hours, put it in a multifunctional extraction tank, add water to extract twice, add 5 to 8 times the amount of water of the total medicinal materials for the first time, extract for 1.5 to 2 hours, and filter the extract. Add 3 to 6 times the amount of water of the total medicinal materials for the second time, extract for 1 to 1.2 hours, take two extracts, filter, take the filtrate, dry it under reduced pressure, and prepare it into granules, powders, tablets, capsules, pills or mixtures with pharmaceutically acceptable carriers.

[0028] As a preferred solution, the preparation method of the above-mentioned Chinese medicine composition for treating polycystic ovary syndrome, the extraction method includes decoction method, reflux extraction method or Soxhlet extraction method.

[0029] When the tablets are prepared, the extract of the traditional Chinese medicine compound composition is added with carrier lactose or corn starch, and lubricant magnesium stearate is added when necessary, mixed evenly, and then compressed into tablets.

[0030] When preparing the capsules, the extract of the Chinese medicine compound composition is added with carrier lactose or corn starch, mixed evenly, granulated, and then filled into capsules to prepare the capsules.

[0031] When preparing the granules, the extract of the Chinese medicine compound composition and the diluent lactose or corn starch are uniformly mixed, granulated, and dried to prepare the granules.

[0032] The present invention has been through a large number of clinical practices and multiple experimental studies, and follows the principle of "monarch, minister, assistant and messenger". In the prescription, Polygonatum sibiricum is the monarch drug, which is sweet, flat and moist, nourishes the kidney and yin, and nourishes the spleen and lungs. It is a wonderful medicine for replenishing essence and marrow. Scrophularia ningpoensis and Radix Ophiopogonis nourish yin and benefit the kidney, and are monarch drugs together with Polygonatum sibiricum. Poria removes dampness and strengthens the spleen, Atractylodes macrocephala dries dampness and strengthens the spleen, one rises and the other falls, so as to stop the source of phlegm, and phlegm turbidity is transformed; Magnolia officinalis dries dampness and resolves phlegm, promotes qi and eliminates accumulation, mainly attacks cold phlegm, and strives to remove phlegm evil in the body, and are minister drugs together. Millettia spatholobi is bitter, sweet and warm in nature, which can both activate blood circulation and replenish blood, and can be used for blood deficiency and blood stasis. Stir-fried red peony root tastes bitter and cools in nature, can clear heat and cool blood, and activate blood circulation and disperse blood stasis. Purple Salvia miltiorrhiza has the same function as the four substances, tastes bitter and is slightly cold in nature, can remove blood stasis and dredge menstruation, so as to enhance the effect of nourishing blood and activating blood circulation. Cinnamon twig tastes spicy and sweet, is warm in nature, warms the meridians, and helps yang and transforms qi. Millettia reticulata, red peony root, salvia miltiorrhiza, and cinnamon twig are used as the guiding drugs to nourish blood, regulate menstruation, and promote blood circulation and remove blood stasis. Amethyst is sweet and warm in nature, and is the key drug for warming the uterus and helping pregnancy. It nourishes the kidney and warms the yang, warms the uterus and dispels cold to promote qi and blood, and helps to resolve phlegm and dampness. It also means "seeking yin in yang" and "nourishing yin without forgetting yang". Gleditsia sinensis is pungent and warm to unblock the meridians. Processed Cyperus rotundus regulates qi and relieves stagnation, soothes the liver and relieves phlegm, and can relieve depression and phlegm. It is matched with Atractylodes macrocephala to open phlegm and disperse knots to help qi and blood be full and replenish without stagnation. "If you want to nourish the kidney, you must first calm your heart. If your heart is calm, your kidney will be full." Forged dragon teeth calm the heart and soothe the nerves. It is paired with Rehmannia glutinosa to connect the heart and kidney. This prescription is designed to nourish the kidney and calm the heart to treat the root cause, resolve phlegm and promote blood circulation to treat the symptoms, and treat both the symptoms and the root cause, so it can regulate menstruation and help pregnancy.

[0033] Beneficial effects: The Chinese medicine composition for treating polycystic ovary syndrome provided by the present invention has the following advantages compared with the prior art:

[0034] The Chinese medicine composition for treating polycystic ovary syndrome provided by the present invention is obtained by accumulating clinical experience for many years, summarizing the main pathogenesis of polycystic ovary syndrome, and continuously streamlining and screening in clinical application under the guidance of traditional Chinese medicine theory. Clinical experimental results show that the Chinese medicine composition provided by the present invention can not only effectively and continuously improve the TCM syndrome score of patients with polycystic ovary syndrome, adjust the menstrual cycle, and improve clinical symptoms such as acne and hirsutism of patients, but also has the multiple effects of reducing the patient's androgen level, luteinizing hormone level, luteinizing hormone / follicle stimulating hormone ratio, fasting insulin level, etc., and improving the polycystic state of the ovary under ultrasound. Therefore, the Chinese medicine composition provided by the present invention has a good effect of treating polycystic ovary syndrome, has no toxic side effects, and is safe and reliable for medication. DETAILED DESCRIPTION

[0035] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the specific material ratios, process conditions and results described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.

[0036] Example 1

[0037] A Chinese medicine composition for treating polycystic ovary syndrome is prepared from the following raw materials in parts by weight:

[0038] 10g of Polygonatum sibiricum, 10g of Scrophularia ningpoensis, 10g of Ophiopogon japonicus, 10g of Poria cocos, 10g of processed Atractylodes lancea, 6g of Magnolia officinalis, 10g of stir-fried Red Peony Root, 10g of Salvia miltiorrhiza, 15g of Millettia reticulata, 10g of processed Cyperus rotundus, 10g of Amethyst, 10g of Gleditsia sinensis, 10g of Cassia twig, and 20g of calcined Dragon's Tooth.

[0039] 2. A method for preparing a Chinese medicine composition for treating polycystic ovary syndrome, comprising the following steps:

[0040] (1) Take 10g of Polygonatum sibiricum, 10g of Scrophularia ningpoensis, 10g of Radix Ophiopogonis, 10g of Poria cocos, 10g of processed Atractylodes lancea, 6g of Magnolia officinalis, 10g of stir-fried Paeonia lactiflora, 10g of Radix Salviae Miltiorrhizae, 15g of Millettia reticulatae, 10g of processed Cyperus rotundus, 10g of Amethyst, 10g of Gleditsia sinensis, 10g of Cinnamomum cassiae, and 20g of calcined Dragon's Tooth. First, add 5 times the amount of water to soak for 1 hour, place in a multi-functional extraction tank, decoct and extract for 2 hours, and filter the decoction. For the second time, add 3 times the amount of water of the total amount of medicinal materials, decoct for 1.2 hours, take the two decoctions, filter, take the filtrate into a heat-sealed bag, sterilize at 105°C, and package.

[0041] Example 2

[0042] A Chinese medicine composition for treating polycystic ovary syndrome is prepared from the following raw materials in parts by weight:

[0043] 30g of Polygonatum sibiricum, 30g of Scrophularia ningpoensis, 30g of Ophiopogon japonicus, 30g of Poria cocos, 30g of processed Atractylodes lancea, 18g of Magnolia officinalis, 30g of stir-fried Red Peony Root, 30g of Salvia miltiorrhiza, 45g of Millettia reticulata, 30g of processed Cyperus rotundus, 30g of Amethyst, 30g of Gleditsia sinensis, 30g of Cassia twig, and 60g of calcined Dragon's Tooth.

[0044] 2. A method for preparing a Chinese medicine composition for treating polycystic ovary syndrome, comprising the following steps:

[0045] Take 30g of polygonatum, 30g of figwort, 30g of ophiopogon, 30g of yunfuling, 30g of processed atractylodes, 18g of magnolia bark, 30g of stir-fried red peony root, 30g of purple salvia miltiorrhiza, 45g of millettia reticulata, 30g of processed cyperus, 30g of purple quartz, 30g of gleditsia thorn, 30g of cassia twig, and 60g of calcined dragon tooth, add 8 times the amount of water to soak for 1 hour, put in a multifunctional extraction tank, add water to decoct and extract for 1 hour, take the decoction and filter. Add 6 times the amount of water of the total medicinal materials for the second time, decoct and extract for 1 hour, take the two decoctions, filter, add carrier lactose or corn starch, add lubricant magnesium stearate, mix evenly, and then press into tablets.

[0046] Example 3

[0047] 1. A Chinese medicine composition for treating polycystic ovary syndrome, which is made from the following raw materials in parts by weight:

[0048] 60g of Polygonatum sibiricum, 60g of Scrophularia ningpoensis, 60g of Ophiopogon japonicus, 60g of Poria cocos, 60g of processed Atractylodes lancea, 36g of Magnolia officinalis, 60g of stir-fried Red Peony Root, 60g of Salvia miltiorrhiza, 90g of Millettia reticulata, 60g of processed Cyperus rotundus, 60g of Amethyst, 60g of Gleditsia sinensis, 60g of Cassia twig, and 120g of calcined Dragon's Tooth.

[0049] 2. A method for preparing a Chinese medicine composition for treating polycystic ovary syndrome, comprising the following steps:

[0050] First, take 60g of Polygonatum sibiricum, 60g of Scrophularia ningpoensis, 60g of Ophiopogon japonicus, 60g of Poria cocos, 60g of processed Atractylodes lancea, 36g of Magnolia officinalis, 60g of stir-fried Red Peony Root, 60g of Salvia miltiorrhiza, 90g of Millettia reticulata, 60g of processed Cyperus rotundus, 60g of Amethyst, 60g of Gleditsia sinensis, 60g of Cinnamomum cassia, and 120g of calcined Dragon's Tooth. For the first time, add 10 times the amount of water of the total amount of medicinal materials and soak for 2 hours, then decoct and extract for 2 hours. For the second time, add 8 times the amount of water of the total amount of medicinal materials and decoct and extract for 1.2 hours. Combine the decoctions, filter, take the filtrate and concentrate under reduced pressure, take the concentrate and add carrier lactose or corn starch to mix evenly, whole the grains, and then fill into capsules to make capsules.

[0051] Example 4

[0052] 1. A Chinese medicine composition for treating polycystic ovary syndrome, which is made from the following raw materials in parts by weight:

[0053] 20g of Polygonatum sibiricum, 20g of Scrophularia ningpoensis, 20g of Ophiopogon japonicus, 20g of Poria cocos, 20g of processed Atractylodes lancea, 12g of Magnolia officinalis, 10g of stir-fried Red Peony Root, 10g of Salvia miltiorrhiza, 30g of Millettia reticulata, 10g of processed Cyperus rotundus, 10g of Amethyst, 10g of Gleditsia sinensis, 10g of Cassia twig, and 20g of calcined Dragon's Tooth.

[0054] 2. A method for preparing a Chinese medicine composition for treating polycystic ovary syndrome, comprising the following steps:

[0055] (1) First, take 20g of polygonatum, 20g of scrophularia, 20g of ophiopogon, 20g of yunfuling, 20g of processed atractylodes, 12g of magnolia bark, 10g of stir-fried red peony root, 10g of salvia miltiorrhiza, 30g of millettia reticulata, 10g of processed cyperus, 10g of purple quartz, 10g of gleditsia spinulosa, 10g of cassia twig, and 20g of calcined dragon tooth, add 8 times the amount of water of the total amount of medicinal materials for the first time, soak for 2 hours, then decoct and extract for 2 hours, add 8 times the amount of water of the total amount of medicinal materials for the second time, decoct and extract for 1 hour, combine the decoctions, filter, and concentrate under reduced pressure, mix the concentrate with the diluent lactose or corn starch evenly, granulate, and dry to prepare granules.

[0056] Example 5 Clinical Trial

[0057] 1. Experimental Materials

[0058] 1. Experimental subjects

[0059] From July 2021 to June 2024, 60 patients were admitted to the gynecology clinic of the Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Provincial Hospital of Traditional Chinese Medicine) and diagnosed with polycystic ovary syndrome, who were diagnosed with kidney deficiency and phlegm and blood stasis according to TCM diagnosis.

[0060] (II) Experimental drugs

[0061] 1. The Chinese medicine composition of the present invention: 10g of polygonatum, 10g of scrophularia, 10g of ophiopogon, 10g of yunfuling, 10g of processed atractylodes, 6g of magnolia bark, 10g of stir-fried red peony root, 10g of salvia miltiorrhiza, 15g of millettia, 10g of processed cyperus, 10g of purple quartz, 10g of gleditsia thorn, 10g of cassia twig, and 20g of calcined dragon tooth were prepared according to the method of Example 1. Provided by the Chinese medicine pharmacy of Jiangsu Provincial Hospital of Traditional Chinese Medicine.

[0062] 2. Ethinyl estradiol cyproterone acetate tablets (Diane-35), drug specifications: 21 tablets / box, each tablet contains 2 mg of cyproterone acetate and 0.035 mg of ethinyl estradiol (Imported Drug Registration Certificate No.: H20170209). Provided by the Western Medicine Pharmacy of Jiangsu Provincial Hospital of Traditional Chinese Medicine.

[0063] 2. Experimental Grouping and Treatment Methods

[0064] Experimental groups: A total of 60 patients with polycystic ovary syndrome of kidney deficiency and phlegm and blood stasis type who met the inclusion criteria were randomly divided into two groups, 30 cases in the treatment group and 30 cases in the control group.

[0065] Treatment:

[0066] Control group: Start taking Diane-35 from the 5th day of menstruation (when B-ultrasound shows endometrium <5mm and no dominant follicles in patients with oligomenorrhea or amenorrhea), one tablet per day for 21 consecutive days, and start taking the next cycle of medication from the 5th day after menstruation. Take it for 3 consecutive menstrual cycles.

[0067] Treatment group: The Chinese medicine composition of the present invention was combined with Diane-35 for treatment. The two drugs were taken synchronously for 21 days. The next cycle of medication began on the 5th day after the menstruation, and the medication was taken continuously for 3 menstrual cycles. Method of taking Chinese medicine: The decoction was prepared according to the method of Example 1. The daily dose was 2 times / day, 150 ml / time, and taken in the morning and evening after warming.

[0068] 3. Observation indicators

[0069] 1. General information: patient's age, height, weight, course of disease, menstrual history, pregnancy and delivery history, health history, medication history, etc. (See Appendix 1).

[0070] 2. Efficacy indicators:

[0071] (1) Acne

[0072] According to the Plewig and Kligman Score acne scoring standard, acne can be diagnosed if the total score is ≥1. (See Appendix 2 for details)

[0073] (2) Hairy

[0074] The Feriman-Gallwey (FG) scoring method is used to score the presence and amount of hair in nine parts of the human body. If the total score is ≥5 points, it is judged as hirsutism.

[0075] (3) TCM symptom scoring: score once before treatment, after 3 menstrual cycles of treatment, and after 3 months of stopping medication. (See Appendix 3 for details)

[0076] (4) Fasting blood glucose (FBG) and fasting insulin (FINS): The changes of FBG and FINS before and after treatment were observed in the two groups. After the subjects fasted for 8 to 10 hours, venous blood was drawn on an empty stomach in the morning of the next day. FBG was detected by the hexokinase method, and FINS was detected by the enzyme-linked immunosorbent assay (ELISA) method, which was tested by the Laboratory Department of Jiangsu Provincial Hospital of Traditional Chinese Medicine.

[0077] (5) Sex hormones: The changes of sex hormones, including testosterone (T), luteinizing hormone (LH), follicle stimulating hormone (FSH), LH / FSH, estradiol (E2), and prolactin (PRL) were observed in the two groups before and after treatment. Venous blood was drawn from the subjects at 8:00-9:00 a.m. on the 2nd to 4th day of the menstrual cycle on an empty stomach, and the chemiluminescence method was used to detect and calculate LH / FSH. The test was conducted by the Laboratory Department of Jiangsu Provincial Hospital of Traditional Chinese Medicine.

[0078] (6) Ultrasound examination: Observe the bilateral ovarian volume and antral follicle count (AFC) before and after treatment. The examination was conducted by the Ultrasound Department of Jiangsu Provincial Hospital of Traditional Chinese Medicine, using EVoluson E8 ultrasound diagnostic instrument with a probe frequency of 5 to 9 MHz.

[0079] 3. Safety indicators:

[0080] (1) General examination items: blood routine, liver function, and kidney function;

[0081] (2) Adverse reactions and side effects after taking the medicine, such as diarrhea, nausea, vomiting, dizziness, abdominal distension, etc.

[0082] 4. Diagnostic Criteria

[0083] 1. TCM diagnostic criteria

[0084] Refer to the "Guidelines for Clinical Research of New Chinese Medicines" (2002 edition) and "Chinese Medicine Gynecology" (the "Thirteenth Five-Year Plan" textbook for higher education in the national traditional Chinese medicine industry, the tenth edition) for the Chinese medicine diagnostic criteria for menstrual disorders of kidney deficiency and phlegm and blood stasis:

[0085] Main symptoms: late menstruation or even amenorrhea, scanty menstruation, or continuous metrorrhagia, obesity and excessive hair growth.

[0086] Secondary symptoms: soreness of waist and knees, fullness and tightness in chest and flanks, fatigue, fear of cold, greasy mouth and excessive phlegm.

[0087] Tongue and pulse: The tongue is dark red or light dark, with petechiae or purple spots, the tongue is enlarged or has teeth marks, the tongue coating is thin white or greasy white or greasy yellow, the pulse is deep and thin or deep and stringy or thin and smooth.

[0088] The diagnosis can be made if one main symptom and two or more secondary symptoms are present, along with the tongue and pulse.

[0089] 2. Western medicine diagnostic criteria

[0090] The diagnostic criteria for PCOS are based on the 2018 Chinese Guidelines for the Diagnosis and Treatment of Polycystic Ovary Syndrome by the Endocrinology Group of the Chinese Society of Obstetrics and Gynecology and the Guideline Expert Group: 1) Oligomenorrhea or amenorrhea or irregular uterine bleeding. 2) Clinical manifestations of hyperandrogenism or hyperandrogenemia. 3) Ultrasound shows polycystic ovarian changes [one or both ovaries have more than 12 follicles with a diameter of 2 to 9 mm and (or) an ovarian volume greater than 10 mL]. 1) is a must, and at least one of 2) and 3) must be present. At the same time, patients with hyperandrogenemia caused by other reasons, such as Cushing syndrome, atypical congenital adrenal hyperplasia, and ovarian or adrenal androgen-secreting tumors, are excluded; patients with ovulatory dysfunction caused by other reasons, such as hypothalamic-pituitary dysfunction, thyroid disease, hyperprolactinemia, and ovarian insufficiency, etc.

[0091] V. Criteria for determining efficacy

[0092] 1. Criteria for determining the efficacy of TCM syndromes

[0093] The method is formulated in accordance with the Guiding Principles for Clinical Research of New Chinese Medicines and is determined by the integral method:

[0094] Therapeutic index (n) = (score before treatment - score after treatment) / score before treatment × 100%

[0095] (1) Cured: All symptoms disappear completely after treatment, and the TCM syndrome score decreases by ≥95%.

[0096] (2) Significantly effective: all symptoms improved significantly after treatment, with the TCM syndrome score decreasing by 70% ≤ and <95%;

[0097] (3) Effective: All symptoms improved slightly after treatment, and the TCM syndrome score decreased by 30% ≤ <70%;

[0098] (4) Ineffective: No change in symptoms after treatment, and the TCM syndrome score decreased by less than 30%

[0099] 3. Comprehensive efficacy evaluation standards: with reference to the Guiding Principles for Clinical Research of New Chinese Medicines (2002 edition), Obstetrics and Gynecology (8th edition), Practical Gynecological Endocrinology, and Chinese Medicine Gynecology (the 13th Five-Year Plan Textbook for National Higher Education in the Traditional Chinese Medicine Industry, 10th edition), etc., the following standards are formulated:

[0100] 4. (1) Cured: The menstrual cycle, menstrual volume, and menstrual period return to normal, all clinical symptoms and signs disappear or almost disappear, laboratory test indicators return to normal, and the TCM syndrome score decreases by ≥90%;

[0101] (2) Markedly effective: menstrual cycle is restored, clinical symptoms and signs are significantly improved, laboratory test indicators are restored to a certain extent, and the score is reduced by ≥70% and <90%;

[0102] (3) Effective: After treatment, the menstrual cycle, menstrual volume, and menstrual period are improved compared with those before treatment, and various clinical symptoms, signs, and laboratory test indicators are restored to a certain extent, with the score reduced by ≥30% and <70%;

[0103] (4) Ineffective: After treatment, there was no improvement in the menstrual cycle, menstrual volume, and menstrual period, and there was no significant change in clinical symptoms, signs, and laboratory test indicators, with a score reduction of <30%.

[0104] Total effective rate = (cured + markedly effective + effective) ÷ total cases × 100%.

[0105] 6. Data Processing

[0106] SPSS 22.0 was used for statistical analysis of the experimental data. The measurement data were analyzed using the t test (X ± S) (homogeneous variance) or the rank sum test (uneven variance), and the count data were analyzed using the X 2 Test, rank data were analyzed with Ridit analysis or rank sum test, P < 0.05 indicated that the difference was statistically significant, and P < 0.01 was a significant difference.

[0107] 7. Experimental results:

[0108] 1. The effect of the Chinese medicine compound composition provided by the present invention on the overall therapeutic effect is shown in Table 1:

[0109] Table 1 Effect on overall efficacy (X2)

[0110] Group Number of cases get well Significant effect efficient invalid Total Effectiveness Treatment Group 30 5 14 10 1 96.67% Control group 30 0 5 20 5 83.33%

[0111] Note: The total efficacy of the two groups was X 2 Test, P<0.05, with statistical significance.

[0112] 2. The effect of the Chinese medicine compound composition provided by the present invention on the TCM symptom score is shown in Table 2:

[0113] Table 2 The impact of TCM symptom scores on PCOS patients

[0114] Group Number of cases Before treatment After treatment 3 months after stopping medication Treatment Group 30 19.93±3.30 <![CDATA[5.93±3.87 **## ]]> <![CDATA[6.08±4.11 ** ]]> Control group 30 21.53±2.92 <![CDATA[9.79±4.85 ** ]]> 21.13±3.81

[0115] Note: The TCM syndrome scores of the two groups of patients were compared before treatment, P>0.05, with no statistical difference. Compared with this group before treatment, **P<0.01, there was a significant statistical difference; compared with the control group after treatment, ## P<0.01, there is a significant statistical difference.

[0116] 3. The effect of the Chinese medicine compound composition provided by the present invention on the acne score of PCOS patients. The results are shown in Table 3:

[0117] Table 3 Effect of acne scores on PCOS patients

[0118] Group Number of cases Before treatment After treatment Treatment Group 30 1.83±0.77 <![CDATA[0.45±0.31 **# ]]> Control group 30 1.92±0.86 <![CDATA[0.90±0.40 ** ]]>

[0119] Note: There was no statistical difference in the acne scores between the two groups before treatment (P>0.05). ** P<0.01, there is a significant statistical difference; compared with the control group after treatment, # P<0.05, there is statistical difference.

[0120] 4. The effect of the Chinese medicine compound composition provided by the present invention on the hirsutism score of PCOS patients. The results are shown in Table 4:

[0121] Table 4 Effect on hirsutism scores in PCOS patients

[0122] Group Number of cases Before treatment After treatment Treatment Group 30 6.79±1.88 5.69±1.34* Control group 30 6.80±0.97 6.70±1.60

[0123] Note: There was no statistical difference in the hirsutism scores between the two groups before treatment (P>0.05). There was a statistical difference (*P<0.05) between the two groups before treatment.

[0124] 5. The effect of the Chinese medicine compound composition provided by the present invention on FBG and FINS of PCOS patients. The results are shown in Table 5:

[0125] Table 5 Effects of FBG and FINS on PCOS patients

[0126]

[0127] Note: There was no statistical difference in FBG and FINS between the two groups before treatment (P>0.05). There was a significant statistical difference (**P<0.01) compared with the group before treatment.

[0128] 6. The effect of the Chinese medicine compound composition provided by the present invention on sex hormones in PCOS patients. The results are shown in Table 6:

[0129] Table 6 Effects on sex hormones in PCOS patients

[0130]

[0131] Note: There was no statistical difference in sex hormones between the two groups before treatment (P>0.05). There was a statistical difference (*P<0.05) between the two groups before treatment and the control group after treatment. # P<0.05, there is statistical difference.

[0132] 7. The effect of the Chinese medicine compound composition provided by the present invention on the ovarian volume and AFC of PCOS patients. The results are shown in Table 7:

[0133] Table 7 Effects of ovarian hormones and AFC in PCOS patients

[0134]

[0135] Note: There was no statistical difference in ovarian volume and AFC between the two groups before treatment (P>0.05). There was a statistical difference (*P<0.05) between the two groups before treatment and the control group after treatment (#P<0.05).

[0136] The above experimental results show that (1) Overall efficacy: The total effective rate of the treatment group was 96.67%, and the total effective rate of the control group was 83.33%. After the test, P<0.05, there was a statistical difference between the two groups. This shows that both groups of drugs are effective in treating PCOS, but the efficacy of the treatment group is better than that of the control group. (2) Effect on the TCM symptom scores of patients: The TCM symptom scores of the two groups before and after treatment were P<0.01, with significant statistical differences, indicating that both groups of drugs can improve the clinical symptoms of patients. The inter-group comparison after treatment was P<0.01, with significant statistical differences, indicating that the efficacy of the treatment group was significantly better than that of the control group. After stopping the drug for 3 months, the TCM symptom scores of the treatment group before and after treatment were P<0.01, with significant statistical differences, indicating that the treatment group has long-term efficacy; the control group P>0.05, no statistical difference. (3) Effect on the acne score of PCOS patients: The acne score of the two groups before and after treatment was P<0.01, with significant statistical differences, indicating that both groups of drugs can improve the acne symptoms of patients. The comparison between the two groups after treatment was P<0.05, which was statistically significant, indicating that the treatment group had better efficacy than the control group. (4) Effect on the hirsutism score of PCOS patients: The comparison of the hirsutism score of the treatment group before and after treatment was P<0.05, which was statistically significant, and the comparison of the hirsutism score of the control group before and after treatment was P>0.05, which was not statistically significant, indicating that the treatment group drugs can improve the hirsutism of patients, and the control group has no therapeutic effect on the hirsutism of patients. (5) Effect on FBG and FINS of patients: Before and after treatment, the effects on FBG of the two groups were P>0.05, which was not statistically significant, indicating that the treatment of the two groups had no effect on FBG. The effects on FINS of the treatment group before and after treatment were P<0.01, which was statistically significant, indicating that the treatment group drugs can significantly reduce the FINS level of patients; the control group P>0.05, which was not statistically significant. (6) Effect on sex hormones of PCOS patients: Before and after treatment, the T value, LH value, and LH / FSH value of the two groups were P<0.05, which was statistically significant, indicating that the two groups of drugs can reduce the T level, LH level and LH / FSH value of patients. The FSH values ​​of the two groups before and after treatment were P>0.05, indicating that the two groups had no effect on the FSH level. The effect on T level, after treatment, the inter-group comparison was P<0.05, indicating that the treatment group had better efficacy than the control group. (7) Effect on the ovarian volume and AFC of patients: Before and after treatment, the ovarian volume and AFC of the two groups were P<0.05, with statistical differences, indicating that both groups of treatment can effectively improve the polycystic ovary state of PCOS patients. After treatment, the inter-group comparison was P<0.05, with statistical differences, indicating that the treatment group had better efficacy than the control group.

[0137] The experimental results show that the Chinese medicine compound composition provided by the present invention can significantly and continuously improve the TCM symptom score of patients with polycystic ovary syndrome, adjust the menstrual cycle, improve patients' acne and hirsutism, reduce patients' T level, LH level, LH / FSH ratio and FINS level, improve the polycystic ovarian state under ultrasound, and has a good effect in treating polycystic ovary syndrome.

[0138] The above implementation modes are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with this technology to understand the content of the present invention and implement it, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

[0139] Appendix 1 General Information

[0140] Name Age Home Address Contact Information

[0141] Chief complaint

[0142] Marital status: Single Married Pregnancy history: premature abortion (spontaneous abortion: medical abortion: uterine curettage: ectopic pregnancy: induction of labor: normal delivery: cesarean section:)

[0143] Menstrual history: menarche age, menstrual cycle days, menstrual period days, last menstrual period time Past medical history: None

[0144] Medication history: None

[0145] Course of disease: Time of first onset Time of first visit

[0146] Appendix 2

[0147] Plewig and Kligman Score acne scoring standard

[0148] type Clinical manifestations score none none 0 slight Acne ≥ 2 mm, < 10 on face or free trunk 1 light Acne 10-20 2 middle Acne > 20 or pustules < 20 3 Heavy Pustules ≥ 20 4

[0149] Appendix III TCM Symptom Scoring Standards

[0152]

Claims

1. A Chinese medicine composition for treating polycystic ovary syndrome, characterized in that: It is made of the following raw materials in parts by weight: 10-60 parts of polygonatum, 10-60 parts of figwort, 10-60 parts of ophiopogon, 10-60 parts of tuckahoe, 10-60 parts of 10-60 parts of processed Atractylodes lancea, 6-36 parts of Magnolia officinalis, 10-60 parts of stir-fried Red Peony Root, 10-60 parts of Red Salvia miltiorrhiza Millettia reticulata 15-90 parts, Cyperus rotundus 10-60 parts, Amethyst 10-60 parts, Gleditsia sinensis 10-60 parts 10-60 parts of cinnamon twigs and 20-120 parts of calcined dragon teeth.

2. The Chinese medicine composition for treating polycystic ovary syndrome according to claim 1, characterized in that: It is made of the following raw materials in parts by weight: 10-30 parts of Polygonatum sibiricum, 10-30 parts of Scrophularia ningpoensis, 10-30 parts of Ophiopogon japonicus, 10-30 parts of Poria cocos 10-30 parts of processed Atractylodes lancea, 6-18 parts of Magnolia officinalis, 10-30 parts of stir-fried Red Peony Root, 10-30 parts of Red Salvia miltiorrhiza Millettia reticulata 10-45 parts, Cyperus rotundus 10-30 parts, Amethyst 10-30 parts, Gleditsia sinensis 10-30 parts 10-30 parts of cinnamon twigs and 20-60 parts of calcined dragon teeth.

3. The Chinese medicine composition for treating polycystic ovary syndrome according to claim 2, characterized in that: It is made of the following raw materials in parts by weight: 10 parts of polygonatum, 10 parts of figwort, 10 parts of ophiopogon, 10 parts of tuckahoe, 10 parts of 10 parts of processed Atractylodes lancea, 6 parts of Magnolia officinalis, 10 parts of stir-fried Red Peony Root, 10 parts of Red Salvia miltiorrhiza 15 parts of Millettia reticulata, 10 parts of processed Cyperus rotundus, 10 parts of Amethyst, 10 parts of Gleditsia sinensis, 10 parts of 10 parts of cinnamon twigs and 20 parts of calcined dragon teeth.

4. The method for preparing the Chinese medicine composition for treating polycystic ovary syndrome according to any one of claims 1 to 3, characterized in that: The following steps are involved: Take polygonatum, scrophularia, ophiopogon, tuckahoe, processed atractylodes, magnolia bark, stir-fried red peony root, salvia miltiorrhiza, millettia reticulata, processed cyperus, purple quartz, sapodilla thorn, cassia twig, and calcined dragon tooth according to weight proportions, first soak them in water, then put them in a multifunctional extraction tank, add water to extract, combine the extracts, and concentrate; take the concentrate and a pharmaceutically acceptable carrier to prepare a traditional Chinese medicine preparation.

5. The method for preparing the Chinese medicine composition for treating polycystic ovary syndrome according to claim 4, characterized in that: The following steps are involved: Take processed polygonatum, scrophularia, ophiopogon, tuckahoe, processed atractylodes, magnolia bark, stir-fried red peony root, salvia miltiorrhiza, millettia reticulata, processed cyperus, purple quartz, sapodilla thorn, cassia twig, and calcined dragon tooth by weight, first soak them in 6 to 15 times the amount of water, then extract them in a multifunctional extraction tank for 1 to 2 hours, then add 6 to 15 times the amount of water of the medicinal materials, extract for 1 to 2 hours, filter, combine the secondary extracts, and concentrate; take the concentrate and a pharmaceutically acceptable carrier to prepare a traditional Chinese medicine preparation.

6. The method for preparing the Chinese medicine composition for treating polycystic ovary syndrome according to claim 4, characterized in that: The following steps are involved: First, take polygonatum, scrophularia, ophiopogon, poria, processed atractylodes, magnolia bark, stir-fried red peony root, salvia miltiorrhiza, millettia reticulata, processed cyperus, purple quartz, sapodilla thorn, cassia twig, and calcined dragon tooth according to weight proportions, soak them in water for 1 to 2 hours, put them in a multifunctional extraction tank, and extract them with water twice. For the first time, add 5 to 8 times the amount of water of the total amount of medicinal materials, extract for 1.5 to 2 hours, and filter the extract; for the second time, add 3 to 6 times the amount of water of the total amount of medicinal materials, extract for 1 to 1.2 hours, take the two extracts, filter, take the filtrate, and prepare it into granules, powders, tablets, capsules, pills or mixtures after reduced pressure drying with a pharmaceutically acceptable carrier.

7. The method for preparing the Chinese medicine composition for treating polycystic ovary syndrome according to any one of claims 4 to 6, characterized in that: Extraction methods include decoction, reflux extraction and Soxhlet extraction.

8. Use of the Chinese medicine composition according to any one of claims 1 to 3 in the preparation of a drug for treating polycystic ovary syndrome.

Citation Information

Patent Citations

  • Chinese medicinal composition for treating polycystic ovary syndrome and preparation method thereof

    CN109200162A

  • Traditional Chinese medicine compound composition for treating polycystic ovarian syndrome ovulation disorder infertility and menstrual disorder and application of traditional Chinese medicine compound composition

    CN118304358A

Cited By

  • Traditional Chinese medicine preparation for nourishing kidney, clearing heat, promoting diuresis and dispersing blood stasis and application thereof

    CN120168581A